C5 and COVID-19: Notably, a multicenter randomized controlled trial involving 368 patients demonstrated that the anti-C5a antibody vilobelimab significantly reduced 28-day mortality and improved survival outcomes in critically ill COVID-19 patients requiring invasive mechanical ventilation (127).